Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
4
×
drugs
life sciences
national blog main
clinical trials
fda
patisiran
rna interference
akcea therapeutics
aminolevulinic acid
givosiran
hereditary transthyretin amyloidosis
inotersen
national top stories
new york blog main
new york top stories
onpattro
san diego blog main
san diego top stories
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
barry greene
biotech
boston university
dan ollendorf
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
john berk
mary o'donnell
paul matteis
pfizer
regeneron pharmaceuticals
san francisco blog main
What
alnylam
4
×
medicine
rna
4
×
drug
fda
interference
rnai
ago
pharmaceuticals
second
seek
speedy
uses
approval
approve
approves
awaits
biological
cells
cleared
crossed
data
decades
decision
discovered
ema
employ
europe
far
fingers
follows
friday
gene
harmful
historic
hits
indicated
make
market
method
Language
Current search:
alnylam
×
rna
×
" boston top stories "
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision